Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene. - Wikidata - awgldk - TriplyDB

Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene.

Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene.

http://www.wikidata.org/entity/Q36298623

about

Advances of gene therapy for primary immunodeficiencies Gene therapy for primary immunodeficiencies Human RAG mutations: biochemistry and clinical implications Long-term reproducible expression in human fetal liver hematopoietic stem cells with a UCOE-based lentiviral vector Gene therapy for inherited immunodeficiency.Design of a regulated lentiviral vector for hematopoietic stem cell gene therapy of globoid cell leukodystrophy Current progress on gene therapy for primary immunodeficiencies.Gene therapy for monogenic disorders of the bone marrow.Stem cell transplantation for the treatment of immunodeficiency in children: current status and hopes for the future.Safe and Efficient Gene Therapy for Pyruvate Kinase Deficiency Characterization of a core region in the A2UCOE that confers effective anti-silencing activity.Common variable immunodeficiency and natural killer cell lymphopenia caused by Ets-binding site mutation in the IL-2 receptor γ (IL2RG) gene promoter.Efficacy of lentiviral mediated gene therapy in an Omenn syndrome Rag2 mouse model is not hindered by inflammation and immune dysregulation.Preclinical Efficacy and Safety Evaluation of Hematopoietic Stem Cell Gene Therapy in a Mouse Model of MNGIE.

P2860

Q26742031-326B7885-22A8-4AA7-B4AD-97629B6FD1B1 Q26864856-BEAE29AD-672D-4551-B08E-FC73942AC71B Q28274274-04C14E66-381F-42CD-8CDB-693DA66A13A6 Q34035474-1F785C2E-81E6-437A-8917-2B3B2FBFAE84 Q34419791-2D037637-0EF8-40CB-87EF-2496B7CA6309 Q36160360-5E0BFD90-85B8-40B3-8BFD-01B85878A2A1 Q38110363-383B4134-0D25-4065-9581-5634190570D6 Q38516548-075368F1-A4C7-4FF7-9F61-BB6B5AB72E10 Q38735833-3B93F2A9-D70C-49B8-AD0D-9133FCB4FD19 Q40772336-FBD68D93-F097-4238-A507-2F0BAD673BF5 Q41579841-BED9C668-5FFD-41B8-B54A-D3C283538A38 Q42624016-A35DECB0-42EB-4199-83A3-8F05208834D5 Q45875844-3C495596-6D2A-45FC-A2D9-B02B0D6FC3EA Q52568126-602CAB4F-7CBE-4973-B559-7AA91341581B

P2860

Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene.

http://www.wikidata.org/entity/Q36298623

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Correction of murine Rag2 seve ...... ed RAG2 therapeutic transgene.

@ast

Correction of murine Rag2 seve ...... ed RAG2 therapeutic transgene.

@en

type

label

Correction of murine Rag2 seve ...... ed RAG2 therapeutic transgene.

@ast

Correction of murine Rag2 seve ...... ed RAG2 therapeutic transgene.

@en

prefLabel

Correction of murine Rag2 seve ...... ed RAG2 therapeutic transgene.

@ast

Correction of murine Rag2 seve ...... ed RAG2 therapeutic transgene.

@en

P1433

Q36298623-ABF4483D-54D9-4D78-ACB0-92B76A13EE75

P1476

Q36298623-370E24E0-B80D-429C-8673-44D075F8DC37

P2093

Q36298623-3E583891-88E8-47F2-9161-99B1595B0E53

Q36298623-872679E6-A989-4B15-9BEB-BCA19AF64802

Q36298623-8CDBDA1A-8EAF-471C-A31E-3532E3B329DD

Q36298623-8FD7E4E6-7675-463C-B826-3B5093DE00FE

Q36298623-963DAE03-4985-4266-A1F9-62A09AF1F02C

Q36298623-BDD3C8D5-E993-45E9-A0FF-7D860D95FC9A

Q36298623-D82C8451-248A-44FA-B3E1-F9569D0AB7FD

Q36298623-F0AD2194-2E7C-468C-8211-7D7F3AF933BA

Q36298623-FA9C3C85-ABAC-4C69-BA1F-59BBF37720AF

P2860

Q36298623-0A03F765-EFC0-4636-9EC9-08A373219609

Q36298623-1356C7C3-58A8-46C2-BBFF-D620C3C5EC12

Q36298623-16C00E57-5112-442D-966C-25529B85A8A1

Q36298623-18136C25-D59F-44DA-A25A-8DFE789071E2

Q36298623-19D69B7A-7934-4D82-993B-86CCFC76B3FB

Q36298623-2688E0BD-276B-4E8A-B9F9-CAB41125EB62

Q36298623-29549352-C708-4AFD-A852-210AB1D77AEA

Q36298623-2EA5F99E-0CBF-4541-AEDE-E8124BF00D4F

Q36298623-44B71A84-3F0D-4FD5-A94B-A4853A44CE08

Q36298623-4C5C1C93-45A3-4476-9AF8-826FA1AF230A

P304

Q36298623-AD47D978-C6DD-4CA8-8770-4BD04CCF555A

P31

Q36298623-93043869-536B-46BF-B427-E7B76704085A

P356

Q36298623-64B31892-4AC2-48D8-9AD1-8D0420BA8BD5

P433

Q36298623-F96313FD-7277-412A-B183-B10F8F0EA5C9

P478

Q36298623-5EA2EADB-E07C-4819-939D-E6845A49A202

P50

Q36298623-00EFDA68-B09A-417A-BDF9-844575E4616C

Q36298623-3EB43B84-AE87-4593-BE1C-52738BB5C01E

Q36298623-4D678582-BC74-4FCF-8E62-DD2118C9058E

Q36298623-87828205-2877-4A90-82E1-BCED92F15D55

P577

Q36298623-3019B88C-A4D1-43D4-8DF0-E7AFF3B1BB55

P5875

Q36298623-61CD3F55-1DCA-4080-A60A-14549A6940CF

P698

Q36298623-8DBB3706-EC78-4FE4-9A45-6A6200B333BD

P921

Q36298623-A2527563-5F00-4206-B318-CCAD960A1EB5

P932

Q36298623-0C817AE8-ED1E-47A6-9A22-4E97ACCCAAAD

P356

P1433

Molecular Therapy

P1476

Correction of murine Rag2 seve ...... ed RAG2 therapeutic transgene.

@en

P2093

Agnieszka Wabik

http://www.w3.org/2001/XMLSchema#string

Elena Fontana

http://www.w3.org/2001/XMLSchema#string

Fang Zhang

http://www.w3.org/2001/XMLSchema#string

Gerard Wagemaker

http://www.w3.org/2001/XMLSchema#string

Helen de Boer

http://www.w3.org/2001/XMLSchema#string

Marshall Huston

http://www.w3.org/2001/XMLSchema#string

Niek P van Til

http://www.w3.org/2001/XMLSchema#string

Nomusa Mashamba

http://www.w3.org/2001/XMLSchema#string

Trudi P Visser

http://www.w3.org/2001/XMLSchema#string

P2860

Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing

Quantitative and qualitative changes in V-J alpha rearrangements during mouse thymocytes differentiation: implication for a limited T cell receptor alpha chain repertoire

Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease

Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy

Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration

Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1

RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement

A third-generation lentivirus vector with a conditional packaging system

Somatic generation of antibody diversity

Stem-cell gene therapy for the Wiskott-Aldrich syndrome.

P304

1968-1980

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2012.110

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Pietro Luigi Poliani

Barbara Cassani

Adrian J Thrasher

P577

2012-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225301077

http://www.w3.org/2001/XMLSchema#string

P698

22692499

http://www.w3.org/2001/XMLSchema#string

P921

P932

3464632

http://www.w3.org/2001/XMLSchema#string